Pfizer Mega-Merger Pursuit Overshadows Consumer Slump
This article was originally published in The Tan Sheet
Executive Summary
The firm’s overall performance – revenues down 9% to $11.4 billion and net income down 15% to $2.3 billion – underscores how much Pfizer needs to acquire AstraZeneca after disclosing its pursuit of the U.K. pharma.